Sec. 773 — Briefing on prostate cancer incidence and emerging diagnostic technologies

Statutory text

Not later than 90 days after the date of the enactment of this Act, the Secretary of Defense, in coordination with the Secretary of Veterans Affairs, shall provide to the Committees on Armed Services of the House of Representatives and the Senate and the Committees on Veterans’ Affairs of the House of Representatives and the Senate a briefing on—(1)the status and any preliminary findings of ongoing studies on cancer incidence rates among members of the Armed Forces and veterans, including—(A)the results of and remedial actions taken following the study conducted by the Secretary of Defense on aircrew members of rotary-wing aircraft under section 736 of the National Defense Authorization Act for Fiscal Year 2026 (Public Law 119—60; 139 Stat. 935); and(B)the results of and remedial actions taken following the completion of the study conducted by the Secretary of Veterans Affairs relating to fixed-wing aviators and associated ground crew pursuant to title V of the Sergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxics Act of 2022 (Public Law 117—168) and subsequent related directives;(2)the incidence and prevalence of prostate cancer among members of the Armed Forces and veterans, including any identified elevated risks within specific occupational specialties;(3)an assessment of emerging and advanced prostate cancer screening, diagnostic, and prognostic technologies, including those that are less invasive and capable of determining cancer aggressiveness;(4)the extent to which such technologies are currently available within the military health system and the health care system of the Department of Veterans Affairs; and(5)a plan, including timelines and resource requirements, to evaluate and, as appropriate, implement such technologies within the military health system and the health care system of the Department of Veterans Affairs.